Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years
PURPOSE: At most centers strict age criteria are lacking for eligibility for active surveillance of prostate cancer. Younger men are often counseled to undergo definitive treatment despite limited data on the outcomes of active surveillance in younger men. We compared clinical characteristics and outcomes in men who enrolled in active surveillance at age less than 60 vs 60 years old or older.
MATERIALS AND METHODS: We retrospectively reviewed the records of 2 institutional cohorts of a total of 2,084 men in whom prostate cancer was managed by active surveillance between 1995 and 2016. We compared outcomes in men who began active surveillance at age 60 vs 60 years or older using the Kaplan-Meier method and Cox proportional hazards regression.
RESULTS: We identified 417 and 1,667 men who began active surveillance at younger than 60 and 60 years old or older, respectively, who met study inclusion criteria. At a median followup of 6.2 years we found no significant difference between men younger than 60 and 60 years old or older in the 5-year rates of biopsy progression-free survival (83% vs 83%), treatment-free survival (74% vs 71%), metastasis-free survival (99.7% vs 99.0%) or prostate cancer specific survival (100% vs 99.7%). Of the younger men 131 (31%) ultimately underwent treatment, including for pathological progression in 67% and prostate specific antigen progression in 18%. On multivariate analysis significant predictors of biopsy progression and progression to treatment among younger men were 20% or greater involvement of any core on diagnostic biopsy (HR 2.21, p = 0.003) and prostate specific antigen density 0.15 ng/ml/ml or greater (HR 1.93, p = 0.01).
CONCLUSIONS: Active surveillance is a viable option in select men younger than 60 years with low volume, low risk prostate cancer. However, patients must be surveyed closely and understand the significant likelihood of ultimately requiring treatment.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
The Journal of urology - 201(2019), 4 vom: 01. Apr., Seite 721-727 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salari, Keyan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age factors |
|---|
| Anmerkungen: |
Date Completed 15.05.2019 Date Revised 15.05.2019 published: Print CommentIn: J Urol. 2019 Apr;201(4):727. - PMID 30947474 Citation Status MEDLINE |
|---|
| doi: |
10.1097/JU.0000000000000031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292917910 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292917910 | ||
| 003 | DE-627 | ||
| 005 | 20231225074158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JU.0000000000000031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0976.xml |
| 035 | |a (DE-627)NLM292917910 | ||
| 035 | |a (NLM)30664083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salari, Keyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2019 | ||
| 500 | |a Date Revised 15.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Urol. 2019 Apr;201(4):727. - PMID 30947474 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: At most centers strict age criteria are lacking for eligibility for active surveillance of prostate cancer. Younger men are often counseled to undergo definitive treatment despite limited data on the outcomes of active surveillance in younger men. We compared clinical characteristics and outcomes in men who enrolled in active surveillance at age less than 60 vs 60 years old or older | ||
| 520 | |a MATERIALS AND METHODS: We retrospectively reviewed the records of 2 institutional cohorts of a total of 2,084 men in whom prostate cancer was managed by active surveillance between 1995 and 2016. We compared outcomes in men who began active surveillance at age 60 vs 60 years or older using the Kaplan-Meier method and Cox proportional hazards regression | ||
| 520 | |a RESULTS: We identified 417 and 1,667 men who began active surveillance at younger than 60 and 60 years old or older, respectively, who met study inclusion criteria. At a median followup of 6.2 years we found no significant difference between men younger than 60 and 60 years old or older in the 5-year rates of biopsy progression-free survival (83% vs 83%), treatment-free survival (74% vs 71%), metastasis-free survival (99.7% vs 99.0%) or prostate cancer specific survival (100% vs 99.7%). Of the younger men 131 (31%) ultimately underwent treatment, including for pathological progression in 67% and prostate specific antigen progression in 18%. On multivariate analysis significant predictors of biopsy progression and progression to treatment among younger men were 20% or greater involvement of any core on diagnostic biopsy (HR 2.21, p = 0.003) and prostate specific antigen density 0.15 ng/ml/ml or greater (HR 1.93, p = 0.01) | ||
| 520 | |a CONCLUSIONS: Active surveillance is a viable option in select men younger than 60 years with low volume, low risk prostate cancer. However, patients must be surveyed closely and understand the significant likelihood of ultimately requiring treatment | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a age factors | |
| 650 | 4 | |a prostate-specific antigen | |
| 650 | 4 | |a prostatectomy | |
| 650 | 4 | |a prostatic neoplasms | |
| 650 | 4 | |a watchful waiting | |
| 700 | 1 | |a Kuppermann, David |e verfasserin |4 aut | |
| 700 | 1 | |a Preston, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Dahl, Douglas M |e verfasserin |4 aut | |
| 700 | 1 | |a Barrisford, Glen W |e verfasserin |4 aut | |
| 700 | 1 | |a Efstathiou, Jason A |e verfasserin |4 aut | |
| 700 | 1 | |a Blute, Michael L |e verfasserin |4 aut | |
| 700 | 1 | |a Vesprini, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Loblaw, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Zietman, Anthony L |e verfasserin |4 aut | |
| 700 | 1 | |a Klotz, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Adam S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of urology |d 1945 |g 201(2019), 4 vom: 01. Apr., Seite 721-727 |w (DE-627)NLM000006890 |x 1527-3792 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2019 |g number:4 |g day:01 |g month:04 |g pages:721-727 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JU.0000000000000031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2019 |e 4 |b 01 |c 04 |h 721-727 | ||